117 related articles for article (PubMed ID: 20685117)
1. Discovery of potent HIV integrase inhibitors active against raltegravir resistant viruses.
Le G; Vandegraaff N; Rhodes DI; Jones ED; Coates JA; Lu L; Li X; Yu C; Feng X; Deadman JJ
Bioorg Med Chem Lett; 2010 Sep; 20(17):5013-8. PubMed ID: 20685117
[TBL] [Abstract][Full Text] [Related]
2. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations.
Mouscadet JF; Arora R; André J; Lambry JC; Delelis O; Malet I; Marcelin AG; Calvez V; Tchertanov L
J Mol Recognit; 2009; 22(6):480-94. PubMed ID: 19623602
[TBL] [Abstract][Full Text] [Related]
4. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
[TBL] [Abstract][Full Text] [Related]
5. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
[TBL] [Abstract][Full Text] [Related]
6. Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes.
Pollicita M; Surdo M; Di Santo F; Cortese MF; Fabeni L; Fedele V; Malet I; Marcelin AG; Calvez V; Ceccherini-Silberstein F; Perno CF; Svicher V
J Antimicrob Chemother; 2014 Sep; 69(9):2412-9. PubMed ID: 24860155
[TBL] [Abstract][Full Text] [Related]
7. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
[TBL] [Abstract][Full Text] [Related]
8. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
9. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
Ni XJ; Delelis O; Charpentier C; Storto A; Collin G; Damond F; Descamps D; Mouscadet JF
Retrovirology; 2011 Aug; 8():68. PubMed ID: 21854605
[TBL] [Abstract][Full Text] [Related]
10. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B
J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211
[TBL] [Abstract][Full Text] [Related]
11. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.
Hu Z; Kuritzkes DR
J Acquir Immune Defic Syndr; 2010 Oct; 55(2):148-55. PubMed ID: 20634701
[TBL] [Abstract][Full Text] [Related]
12. [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].
Delaugerre C
Med Mal Infect; 2010 Sep; 40 Suppl 1():S1-10. PubMed ID: 20800182
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.
Nguyen HL; Charpentier C; Nguyen N; de Truchis P; Molina JM; Ruxrungtham K; Delaugerre C
HIV Med; 2013 Feb; 14(2):85-91. PubMed ID: 22994529
[TBL] [Abstract][Full Text] [Related]
14. Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
Charpentier C; Larrouy L; Matheron S; Damond F; Delelis O; Mouscadet JF; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
Antivir Ther; 2011; 16(6):937-40. PubMed ID: 21900727
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.
Canducci F; Ceresola ER; Boeri E; Spagnuolo V; Cossarini F; Castagna A; Lazzarin A; Clementi M
J Infect Dis; 2011 Dec; 204(11):1811-5. PubMed ID: 21984737
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
[TBL] [Abstract][Full Text] [Related]
17. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.
Loizidou EZ; Kousiappa I; Zeinalipour-Yazdi CD; Van de Vijver DA; Kostrikis LG
Biochemistry; 2009 Jan; 48(1):4-6. PubMed ID: 19090674
[TBL] [Abstract][Full Text] [Related]
18. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.
Codoñer FM; Pou C; Thielen A; García F; Delgado R; Dalmau D; Santos JR; Buzón MJ; Martínez-Picado J; Alvarez-Tejado M; Clotet B; Ruiz L; Paredes R
Antiviral Res; 2010 Dec; 88(3):281-6. PubMed ID: 20883724
[TBL] [Abstract][Full Text] [Related]
19. Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses.
Witmer M; Danovich R
Methods; 2009 Apr; 47(4):277-82. PubMed ID: 19286458
[TBL] [Abstract][Full Text] [Related]
20. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.
Fransen S; Gupta S; Danovich R; Hazuda D; Miller M; Witmer M; Petropoulos CJ; Huang W
J Virol; 2009 Nov; 83(22):11440-6. PubMed ID: 19759152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
